Some Do--Some Watch Over Those Who Do

While randomization is required by regulatory bodies, it is up to the sponsor on how to conduct it.

Increased public engagement leads recent change in EMA profile.

Higher costs headline list of new challenges faced by CROs and sponsors.

Cancer still a primary focus of EMA in light of COVID and vaccine development.

Europe's research ministers are will meet to attempt to reach agreement on European Union research plans for the next seven years, including a cluster devoted to a broad range of health goals that range from general objectives to subjects of more specific interest to the community.